Response to Ritlecitinib Treatment Based on Salt Improvement Scores in Patients With Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study

    U. Blume-Peytavi, W. Gubelin Harcha, Q. Yang, G. Schmieder, M.K. Hordinsky, G. Micali, M. Ohyama, L. Takiya, F. Zhang, G. Schaefer, R. Wolk, U. Kerkmann
    TLDR Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
    This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of ritlecitinib in patients aged ≥12 years with alopecia areata (AA) and ≥50% scalp hair loss. Patients received varying doses of ritlecitinib or placebo for 24 weeks, with the placebo group switching to ritlecitinib thereafter. By Week 24, a higher proportion of patients treated with ritlecitinib achieved significant improvements in SALT scores compared to placebo, with 29-43% achieving SALT50, 13-31% achieving SALT75, 9-19% achieving SALT90, and 2-7% achieving SALT100. These improvements continued through Week 48, with 43-55% achieving SALT50, 30-46% achieving SALT75, 21-30% achieving SALT90, and 7-14% achieving SALT100. The study concluded that ritlecitinib treatment leads to significant scalp hair regrowth, with higher doses yielding better results.
    Discuss this study in the Community →


    2 / 2 results